CEVEC is Transforming Vaccine Development starting with Zika
CEVEC Pharmaceuticals recently partnered up with NewLink Genetics to use its CAP technology for the development of new vaccines against the Zika virus. We had the opportunity to ask CEVECs CSO a few questions about how their technology can transform vaccine development.
Labiotech.eu – February 20, 2017
CEVEC Pharmaceuticals is developing high-quality platforms for the efficient and safe production of glycosylated proteins, viral vaccines and gene therapy vectors. Their CAP technology consists of robust cell-lines which are extensively documented and able to be easily scaled up for cost-efficient production processes. With their virus-producing cell lines CAP-GT, CEVEC is making significant contributions to the development of safer vectors for gene therapy. Now they are planning to enter the vaccine market.
Meet the CEO making the Next Generation of Gene Therapies Possible
Labiotech.eu – November 16, 2016
How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success.
The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors as a means of delivery. CEVEC’s contribution is a platform that includes two technologies, CAP-Go for the tailor-made production of previously inaccessible recombinant proteins and CAP-GT for industrial scale production of lentiviral, adenoviral and AAV gene therapy vectors.
CEVEC is Revolutionizing
Industrial Protein & Viral Vector Production
Labiotech.eu – November 3, 2016
CEVEC just filed a Biologics Master File (BB-MF) to the FDA for its CAP technology, which outperforms all current standards in the production of gene therapy vectors and glycosylated human proteins.
This Technology Opens new Horizons for Protein Production
Labiotech.eu – October 19, 2016
Based in Cologne (Germany), Cevec focuses on human cell-based expression system for production of biological therapies. We’ve already covered their breakthroughs for safer gene therapy and the potential of CAP-GT for expression of viral vectors.
Besides CAP-GT, CEVEC has also developed a cell line that can produce complex glycosylated proteins. A good example of glycosylated protein is the therapeutic plasma protein. So far, these proteins have been isolated from donated human plasma by companies like Octapharma (a big company in Zurich’s Biotech ecosystem). With Cevec’s CAP-Go, recombinant plasma proteins can be produced for the first time.
Cevec: “Our Special Cell Lines will help the next generation of Gene Therapy”
Labiotech.eu – September 1, 2016
Cevec could very well be the missing link between adenoviral vectors and approved gene therapies. LABIOTECH had a chat with the CSO of Cevec about what makes its technology great and how it’s ready for the future of gene therapy.
German Biotech partners up in the US for scalable viral vector production in Gene Therapy
Labiotech.eu – July 6, 2016
Cevec is joining forces with US-based Paragon. The objective is to make Cevec’s scalable CAP® expression technology the industry standard for glycoproteins and viral vectors in gene therapies.
Based in Cologne (Germany), Cevec tackles with its human cell-based expression systems CAP®GT and CAP®Go two big challenges in Biotech manufacturing – industrial scale production of viral vectors and complex glycoproteins.
CAP®GT is a platform to produce viral vectors, such as lentivirus (LV) adenovirus (AV) and adeno-associated virus (AAV). These viral vectors are used to carry genetic information to the target cells in the patient’s body in gene therapy.
CEVEC trifft mit Gentherapie-Vektoren ins Schwarze
Interview mit www.transkript.de – March, 2016
Zahlreiche neue Partnerschaften konnte der Expressionsspezialist Cevec Pharmaceuticals für seine CAP-Zelllinien abschließen. Der Geschäftsführer Frank Ubags erläutert im Gespräch mit transkript die ergeizigen Pläne des Kölner Unternehmens.
Novel Method for Glycoprotein Expression
GEN Bioprocessing Tutorial – November 1 Issue, 2015
Silke Wissing, Ph.D., Jens Wölfel, Ph.D., Helmut Kewes, Christian Niehus, Corinna Bialek, Sabine Hertel, and Nicole Faust, Ph.D.
Utilizing CAP-Go Cells for Optimizing Serum Half-Life and Glycosylation Profile
Science Only Accounts For Fifty Percent of a Project’s Success: An interview with Frank Ubags
bio-live.de – November 6, 2015
Interview conducted by Rieke Winter
CEVEC Pharmaceutical’s CEO Frank Ubags on the Technologies Developed by His Company, the Need for Sound Project Management and Dealing With Ethical Conundrums
Scalable production of gene therapy vectors: an interview with Frank Ubags
news-medical.net – October 26, 2015
Interview conducted by April Cashin-Garbutt, MA (Cantab)
Insights from industry Frank Ubags CEO, CEVEC Pharmaceuticals GmbH Gene therapy involves introducing genetic material into cells to replace missing or malfunctioning genes or to add a gene to express a beneficial protein in order to treat certain diseases, such as cancer or inherited disorders. …